Clinical Trials Arena on MSN
Daiichi Sankyo announces first patient dosed in phase III trial of Enhertu
Nearly 580 participants will be enrolled at sites across Europe, Asia, South America, and North America.
Ovarian01 Phase 3 Trial of ENHERTU® Initiated as First-Line Maintenance Therapy in Patients with HER2 Expressing Advanced ...
The first patient has been dosed in the randomization phase of the DESTINY-Ovarian01 phase 3 trial evaluating Enhertu in combination with ...
Philadelphia, PA, USA, December 9, 2025, First Patient Enrolled in GOG-3133/ FRAmework-01 Phase 3 Study Evaluating Sofetabart ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback